explore -WSS

explore

author：entertainment 2025-10-01 17:34:08 - browse：5

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： What PEPFAR has meant on the ground in Ukraine

WSS

Congenital heart disease patients face new threat of heart failure

Covid vaccines: Private market messier than government rollout

Chemotherapy shortages won’t get better under Biden’s latest plan

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Health tech startups drop sharply from 2021 highs

Leukemia patients are helped by Syndax's new type of therapy

focus

explore

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Kaiser Permanente unions announce official strike date

Guidelines to prevent youth baseball injuries need more muscle

Researchers use wearables data and AI to predict preterm birth risk

Hollywood unions extend contract negotiations for actors

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Data show record exodus of life scientists from academia

Hepatitis C has a cure — but many Americans still lack access to it

What PEPFAR has meant on the ground in Ukraine

Wikipedia

How the Dana

FDA advisers vote against ALS treatment from BrainStorm

STAT letters to the editor on burnt

Leukemia patients are helped by Syndax's new type of therapy

Medicare drug price negotiation program allowed for now

In diabetes hearing, Sanders takes on a new foe: food makers

explore

focus

hotspot

hotspot